Teva On Track To Hit Targets With Truxima

Targeting New Patients With US Rituximab Biosimilar

 
• By David Wallace
Teva_Magnified
Teva has forecast sales of $17.2bn-$17.4bn in 2019 • Source: Shutterstock

More from Earnings

More from Business